{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:32Z","timestamp":1794047492826,"version":"4.8.0"},"reference-count":85,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Sickle cell retinopathy (SCR) is a complication of sickle cell disease (SCD) and can drastically impair visual acuity. Screening for SCR is, therefore, recommended, but evidence for optimal screening frequency on an individual level is lacking. This scoping review mapped the current evidence on risk factors for SCR and sickle cell maculopathy (SCM). A literature search (in Medline [Ovid]), Embase [Ovid]), and Scopus) resulted in 67 included articles which covered demographic risk factors, genetic risk factors, systemic therapy, correlations with other forms of SCD-related organ damage, and hematologic risk factors. SCR risk factors include older age, male sex, HbSC genotype, hemolysis, and HbF% &lt;15% (in HbSS) and increased blood viscosity (in HbSC). For SCM, risk factors are older age, HbSS genotype, and higher degree of hemolysis. The pathophysiology of SCR and SCM appears multifactorial, but distinct patterns emerge suggesting that vaso-occlusion and hemolysis cause SCM and NPSCR in HbSS, while hyperviscosity in HbSC leads to peripheral retinopathy. We recommend yearly screening for high-risk patients (older HbSC males) and triennial screening for low-risk patients (young females HbSS with HbF&gt;15%) to ensure comprehensive yet proportionate ophthalmic care. However, future studies are needed on the role of interventions for SCR and the long-term consequences of SCM in order to evaluate and define appropriate screening schedules.<\/jats:p>","DOI":"10.3324\/haematol.2024.286420","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T02:56:40Z","timestamp":1734577000000},"page":"1092-1104","source":"Crossref","is-referenced-by-count":3,"title":["Clinical and laboratory risk factors for sickle cell retinopathy and maculopathy: a scoping review of the current evidence"],"prefix":"10.3324","volume":"110","author":[{"given":"Rajani P.","family":"Brandsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roselie M.H.","family":"Diederen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizem","family":"Kocabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erfan","family":"Nur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"Malekzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinier O.","family":"Schlingemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J.","family":"Biemond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"74798","doi-asserted-by":"crossref","unstructured":"Abdalla Elsayed MEA, Mura M, Al Dhibi H. Sickle cell retinopathy. A focused review. Graefes Arch Clin Exp Ophthalmol. 2019; 257(7):1353-1364.","DOI":"10.1007\/s00417-019-04294-2"},{"key":"74799","doi-asserted-by":"crossref","unstructured":"Andrawes NG, Ismail EA, Roshdy MM, Ebeid FSE, Eissa DS, Ibrahim AM. Angiopoietin-2 as a marker of retinopathy in children and adolescents with sickle cell disease: relation to subclinical atherosclerosis. J Pediatr Hematol Oncol. 2019; 41(5):361-370.","DOI":"10.1097\/MPH.0000000000001486"},{"key":"74800","doi-asserted-by":"crossref","unstructured":"Minvielle W, Caillaux V, Cohen SY. Macular microangiopathy in sickle cell disease using optical coherence tomography angiography. Am J Ophthalmol. 2016; 164:137-144.e1.","DOI":"10.1016\/j.ajo.2015.12.023"},{"key":"74801","doi-asserted-by":"crossref","unstructured":"Hoang QV, Chau FY, Shahidi M, Lim JI. Central macular splaying and outer retinal thinning in asymptomatic sickle cell patients by spectral-domain optical coherence tomography. Am J Ophthalmol. 2011; 151(6):990-994.","DOI":"10.1016\/j.ajo.2010.12.010"},{"key":"74802","doi-asserted-by":"crossref","unstructured":"Martin GC, D\u00e9nier C, Zambrowski O. Visual function in asymptomatic patients with homozygous sickle cell disease and temporal macular atrophy. JAMA Ophthalmol. 2017; 135(10):1100-1105.","DOI":"10.1001\/jamaophthalmol.2017.3008"},{"key":"74803","doi-asserted-by":"crossref","unstructured":"Fadugbagbe AO, Gurgel RQ, Mendon\u00e7a CQ, Cipolotti R, dos Santos AM, Cuevas LE. Ocular manifestations of sickle cell disease. Ann Trop Paediatr. 2010; 30(1):19-26.","DOI":"10.1179\/146532810X12637745451870"},{"key":"74804","doi-asserted-by":"crossref","unstructured":"Sandhu MK, Cohen A. Aging in sickle cell disease: comorbidities and new issues in management. Hemoglobin. 2015; 39(4):221-224.","DOI":"10.3109\/03630269.2015.1040493"},{"key":"74805","doi-asserted-by":"crossref","unstructured":"Yawn BP, Buchanan GR, Afenyi-Annan AN. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014; 312(10):1033-1048.","DOI":"10.1001\/jama.2014.10517"},{"key":"74806","doi-asserted-by":"crossref","unstructured":"Nawaiseh M, Roto A, Nawaiseh Y. Risk factors associated with sickle cell retinopathy: findings from the Cooperative Study of Sickle Cell Disease. Int J Retina Vitreous. 2022; 8(1):68.","DOI":"10.1186\/s40942-022-00419-8"},{"key":"74807","doi-asserted-by":"crossref","unstructured":"Brandsen RP, Diederen RMH, Bakhlakh S, Nur E, Schlingemann RO, Biemond BJ. Natural history and rate of progression of retinopathy in adult patients with sickle cell disease: an 11-year follow-up study. Blood Adv. 2023; 7(13):3080-3086.","DOI":"10.1182\/bloodadvances.2022009147"},{"key":"74808","doi-asserted-by":"crossref","unstructured":"Al Ryalat SA, Jaber BAM, Alzarea AA, Alzarea AA, Alosaimi WA, Al Saad M. Ocular manifestations of sickle cell disease in different genotypes. Ophthalmic Epidemiol. 2021; 28(3):185-190.","DOI":"10.1080\/09286586.2020.1801762"},{"key":"74809","doi-asserted-by":"crossref","unstructured":"Grego L, Pignatto S, Alfier F. Optical coherence tomography (OCT) and OCT angiography allow early identification of sickle cell maculopathy in children and correlate it with systemic risk factors. Graefes Arch Clin Exp Ophthalmol. 2020; 258(11):2551-2561.","DOI":"10.1007\/s00417-020-04764-y"},{"key":"74810","doi-asserted-by":"crossref","unstructured":"Tricco AC, Lillie E, Zarin W. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018; 169(7):467-473.","DOI":"10.7326\/M18-0850"},{"key":"74811","unstructured":"Clarkson JG. The ocular manifestations of sickle-cell disease: a prevalence and natural history study. Trans Am Ophthalmol Soc. 1992; 90:481-504."},{"key":"74812","doi-asserted-by":"crossref","unstructured":"Demb\u00e9l\u00e9 AK, Toure BA, Sarro YS. Prevalence and risk factors for sickle retinopathy in a sub-Saharan comprehensive Sickle Cell Center. Rev Med Interne. 2017; 38(9):572-577.","DOI":"10.1016\/j.revmed.2017.01.010"},{"key":"74813","doi-asserted-by":"crossref","unstructured":"Downes SM, Hambleton IR, Chuang EL, Lois N, Serjeant GR, Bird AC. Incidence and natural history of proliferative sickle cell retinopathy: observations from a cohort study. Ophthalmology. 2005; 112(11):1869-1875.","DOI":"10.1016\/j.ophtha.2005.05.026"},{"key":"74814","doi-asserted-by":"crossref","unstructured":"Duan XJ, Lanzkron S, Linz MO, Ewing C, Wang J, Scott AW. Clinical and ophthalmic factors associated with the severity of sickle cell retinopathy. Am J Ophthalmol. 2019; 197:105-113.","DOI":"10.1016\/j.ajo.2018.09.025"},{"key":"74815","doi-asserted-by":"crossref","unstructured":"Fox PD, Dunn DT, Morris JS, Serjeant GR. Risk factors for proliferative sickle retinopathy. Br J Ophthalmol. 1990; 74(3):172-176.","DOI":"10.1136\/bjo.74.3.172"},{"key":"74816","doi-asserted-by":"crossref","unstructured":"Leveziel N, Bastuji-Garin S, Lalloum F. Clinical and laboratory factors associated with the severity of proliferative sickle cell retinopathy in patients with sickle cell hemoglobin C (SC) and homozygous sickle cell (SS) disease. Medicine (Baltimore). 2011; 90(6):372-378.","DOI":"10.1097\/MD.0b013e3182364cba"},{"key":"74817","doi-asserted-by":"crossref","unstructured":"Saidkasimova S, Shalchi Z, Mahroo OA. Risk factors for visual impairment in patients with sickle cell disease in London. Eur J Ophthalmol. 2016; 26(5):431-435.","DOI":"10.5301\/ejo.5000767"},{"key":"74818","doi-asserted-by":"crossref","unstructured":"Talbot JF, Bird AC, Maude GH, Acheson RW, Moriarty BJ, Serjeant GR. Sickle cell retinopathy in Jamaican children: further observations from a cohort study. Br J Ophthalmol. 1988; 72(10):727-732.","DOI":"10.1136\/bjo.72.10.727"},{"key":"74819","doi-asserted-by":"crossref","unstructured":"Tantawy AA, Andrawes NG, Adly AA, El Kady BA, Shalash AS. Retinal changes in children and adolescents with sickle cell disease attending a paediatric hospital in Cairo, Egypt: risk factors and relation to ophthalmic and cerebral blood flow. Trans R Soc Trop Med Hyg. 2013; 107(4):205-211.","DOI":"10.1093\/trstmh\/trt008"},{"key":"74820","doi-asserted-by":"crossref","unstructured":"Hayes RJ, Condon PI, Serjeant GR. Haematological factors associated with proliferative retinopathy in sickle cell-haemoglobin C disease. Br J Ophthalmol. 1981; 65(10):712-717.","DOI":"10.1136\/bjo.65.10.712"},{"key":"74821","doi-asserted-by":"crossref","unstructured":"El-Ghamrawy MK, El Behairy HF, El Menshawy A, Awad SA, Ismail A, Gabal MS. Ocular manifestations in Egyptian children and young adults with sickle cell disease. Indian J Hematol Blood Transfus. 2014; 30(4):275-280.","DOI":"10.1007\/s12288-014-0333-0"},{"key":"74822","doi-asserted-by":"crossref","unstructured":"Osafo-Kwaako A, Kimani K, Ilako D. Ocular manifestations of sickle cell disease at the Korle-bu Hospital, Accra, Ghana. Eur J Ophthalmol. 2011; 21(4):484-489.","DOI":"10.5301\/EJO.2010.5977"},{"key":"74823","doi-asserted-by":"crossref","unstructured":"Mian UK, Tang J, Allende APM. Elevated fetal haemoglobin levels are associated with decreased incidence of retinopathy in adults with sickle cell disease. Br J Haematol. 2018; 183(5):807-811.","DOI":"10.1111\/bjh.15617"},{"key":"74824","doi-asserted-by":"crossref","unstructured":"Fox PD, Vessey SJ, Forshaw ML, Serjeant GR. Influence of genotype on the natural history of untreated proliferative sickle retinopathy--an angiographic study. Br J Ophthalmol. 1991; 75(4):229-231.","DOI":"10.1136\/bjo.75.4.229"},{"key":"74825","doi-asserted-by":"crossref","unstructured":"Bilong Y, Dubert M, Koki G. Sickle cell retinopathy and other chronic complications of sickle cell anemia: a clinical study of 84 Sub-Saharan African cases (Cameroon). J Fr Ophtalmol. 2018; 41(1):50-56.","DOI":"10.1016\/j.jfo.2017.07.005"},{"key":"74826","doi-asserted-by":"crossref","unstructured":"Martin GC, Albuisson E, Brousse V, de Montalembert M, Bremond-Gignac D, Robert MP. Paramacular temporal atrophy in sickle cell disease occurs early in childhood. Br J Ophthalmol. 2019; 103(7):906-910.","DOI":"10.1136\/bjophthalmol-2018-312305"},{"key":"74827","doi-asserted-by":"crossref","unstructured":"Zulueta P, Minniti CP, Rai A, Toribio TJ, Moon JY, Mian UK. Routine ophthalmological examination rates in adults with sickle cell disease are low and must be improved. Int J Environ Res Public Health. 2023; 20(4):3451.","DOI":"10.3390\/ijerph20043451"},{"key":"74828","doi-asserted-by":"crossref","unstructured":"Talbot JF, Bird AC, Serjeant GR, Hayes RJ. Sickle cell retinopathy in young children in Jamaica. Br J Ophthalmol. 1982; 66(3):149-154.","DOI":"10.1136\/bjo.66.3.149"},{"key":"74829","doi-asserted-by":"crossref","unstructured":"Li J, Bender L, Shaffer J, Cohen D, Ying GS, Binenbaum G. Prevalence and onset of pediatric sickle cell retinopathy. Ophthalmology. 2019; 126(7):1000-1006.","DOI":"10.1016\/j.ophtha.2019.02.023"},{"key":"74830","doi-asserted-by":"crossref","unstructured":"Ghasemi Falavarjani K, Scott AW, Wang K. Correlation of multimodal imaging in sickle cell retinopathy. Retina. 2016; 3(Suppl 1):S111-S117.","DOI":"10.1097\/IAE.0000000000001230"},{"key":"74831","doi-asserted-by":"crossref","unstructured":"Martin GC, Brousse V, Connes P. Retinal atrophy and markers of systemic and cerebrovascular severity in homozygous sickle cell disease. Eur J Ophthalmol. 2022; 32(6):3258-3266.","DOI":"10.1177\/11206721221090794"},{"key":"74832","doi-asserted-by":"crossref","unstructured":"Jin J, Miller R, Salvin J. Funduscopic examination and SD-OCT in detecting sickle cell retinopathy among pediatric patients. J AAPOS. 2018; 22(3):197-201.e1.","DOI":"10.1016\/j.jaapos.2017.12.019"},{"key":"74833","doi-asserted-by":"crossref","unstructured":"Marsh RJ, Ford SM, Rabb MF, Hayes RJ, Serjeant GR. Macular vasculature, visual acuity, and irreversibly sickled cells in homozygous sickle cell disease. Br J Ophthalmol. 1982; 66(3):155-160.","DOI":"10.1136\/bjo.66.3.155"},{"key":"74834","doi-asserted-by":"crossref","unstructured":"Rosenberg JB, Hutcheson KA. Pediatric sickle cell retinopathy: correlation with clinical factors. J AAPOS. 2011; 15(1):49-53.","DOI":"10.1016\/j.jaapos.2010.11.014"},{"key":"74835","doi-asserted-by":"crossref","unstructured":"Leveziel N, Lalloum F, Bastuji-Garin S. Sickle-cell retinopathy: retrospective study of 730 patients followed in a referral center. J Fr Ophtalmol. 2012; 35(5):343-347.","DOI":"10.1016\/j.jfo.2011.10.007"},{"key":"74836","unstructured":"Kaimbo Wa Kaimbo D, Ngiyulu Makuala R, Dralands L, Missotten L. Ocular findings in children with homozygous sickle cell disease in the Democratic Republic of Congo. Bull Soc Belge Ophtalmol. 2000; 275:27-30."},{"key":"74837","doi-asserted-by":"crossref","unstructured":"Talbot JF, Bird AC, Rabb LM, Maude GH, Serjeant GR. Sickle cell retinopathy in Jamaican children: a search for prognostic factors. Br J Ophthalmol. 1983; 67(11):782-785.","DOI":"10.1136\/bjo.67.11.782"},{"key":"74838","doi-asserted-by":"crossref","unstructured":"Idris IM, Yusuf AA, Gwarzo DH. High systolic blood pressure, anterior segment changes and visual impairment independently predict sickle cell retinopathy. Hemoglobin. 2021; 45(4):228-233.","DOI":"10.1080\/03630269.2021.1957927"},{"key":"74839","doi-asserted-by":"crossref","unstructured":"Lim JI, Cao D. Analysis of retinal thinning using spectral-domain optical coherence tomography imaging of sickle cell retinopathy eyes compared to age- and race-matched control eyes. Am J Ophthalmol. 2018; 192:229-238.","DOI":"10.1016\/j.ajo.2018.03.013"},{"key":"74840","doi-asserted-by":"crossref","unstructured":"Oladimeji OI, Adeodu OO, Onakpoya OH, Adegoke SA. Prevalence of ocular abnormalities in relation to sickle cell disease severity among children in South-western, Nigeria. Eur J Ophthalmol. 2021; 31(5):2659-2665.","DOI":"10.1177\/1120672120957615"},{"key":"74841","doi-asserted-by":"crossref","unstructured":"Diallo JW, Sanfo O, Blot I. Epidemiology and prognostic factors for sickle cell retinopathy in Ouagadougou (Burkina Faso). J Fr Ophtalmol. 2009; 32(7):496-500.","DOI":"10.1016\/j.jfo.2009.04.010"},{"key":"74842","doi-asserted-by":"crossref","unstructured":"Gill HS, Lam WC. A screening strategy for the detection of sickle cell retinopathy in pediatric patients. Can J Ophthalmol. 2008; 43(2):188-191.","DOI":"10.3129\/i08-003"},{"key":"74843","doi-asserted-by":"crossref","unstructured":"Bonanomi MT, Cunha SL, de Ara\u00fajo JT. Funduscopic alterations in SS and SC hemoglobinopathies. Study of a Brazilian population. Ophthalmologica. 1988; 197(1):26-33.","DOI":"10.1159\/000309913"},{"key":"74844","doi-asserted-by":"crossref","unstructured":"Condon PI, Serjeant GR. Ocular findings in hemoglobin SC disease in Jamaica. Am J Ophthalmol. 1972; 74(5):921-931.","DOI":"10.1016\/0002-9394(72)91213-5"},{"key":"74845","doi-asserted-by":"crossref","unstructured":"Mokrane A, Gazeau G, L\u00e9vy V, Fajnkuchen F, Giocanti-Aur\u00e9gan A. Analysis of the foveal microvasculature in sickle cell disease using swept-source optical coherence tomography angiography. Sci Rep. 2020; 10(1):11795.","DOI":"10.1038\/s41598-020-68625-8"},{"key":"74846","doi-asserted-by":"crossref","unstructured":"Tran TH, Mekinian A, Godinaud M, Rose C. Screening for sickle cell disease retinopathy in the north of France. J Fr Ophtalmol. 2008; 31(10):987-992.","DOI":"10.1016\/S0181-5512(08)74745-4"},{"key":"74847","doi-asserted-by":"crossref","unstructured":"Aguiar AG, Aguiar LP, Santos VLVd, Oliveira DCdA. Sickle cell retinopathy: characterization among patients over 40 years of age. Rev Bras Oftalmol. 2020; 79(2):118-121.","DOI":"10.5935\/0034-7280.20200015"},{"key":"74848","doi-asserted-by":"crossref","unstructured":"Han IC, Linz MO, Liu TYA, Zhang AY, Tian J, Scott AW. Correlation of ultra-widefield fluorescein angiography and OCT angiography in sickle cell retinopathy. Ophthalmol Retina. 2018; 2(6):599-605.","DOI":"10.1016\/j.oret.2017.10.011"},{"key":"74849","doi-asserted-by":"crossref","unstructured":"Kent D, Arya R, Aclimandos WA, Bellingham AJ, Bird AC. Screening for ophthalmic manifestations of sickle cell disease in the United Kingdom. Eye (Lond). 1994; 8(Pt 6):618-622.","DOI":"10.1038\/eye.1994.155"},{"key":"74850","doi-asserted-by":"crossref","unstructured":"Condon P, Jampol LM, Farber MD, Rabb M, Serjeant G. A randomized clinical trial of feeder vessel photocoagulation of proliferative sickle cell retinopathy. II. Update and analysis of risk factors. Ophthalmology. 1984; 91(12):1496-1498.","DOI":"10.1016\/S0161-6420(84)34121-5"},{"key":"74851","doi-asserted-by":"crossref","unstructured":"Abdelkader A, Shaaban M, Zahran MM, Mohammed MF, Ebrahim AM, Galhoom AI. The impact of optical coherence tomography in the early identification of children with sickle cell retinopathy. Int J Clin Pract. 2022; 2022:9131423.","DOI":"10.1155\/2022\/9131423"},{"key":"74852","doi-asserted-by":"crossref","unstructured":"Jin J, Kandula V, Miller RE. Monitoring retinal pathology and cerebral injury in sickle cell disease using spectral-domain optical coherence tomography in pediatric patients. Pediatr Blood Cancer. 2021; 68(7):e29028.","DOI":"10.1002\/pbc.29028"},{"key":"74853","doi-asserted-by":"crossref","unstructured":"Hussnain SA, Coady PA, Slade MD. Hemoglobin level and macular thinning in sickle cell disease. Clin Ophthalmol. 2019; 13:627-632.","DOI":"10.2147\/OPTH.S195168"},{"key":"74854","doi-asserted-by":"crossref","unstructured":"Fares S, Hajjar S, Romana M. Sickle cell maculopathy: microstructural analysis using OCTA and identification of genetic, systemic, and biological risk factors. Am J Ophthalmol. 2021; 224:7-17.","DOI":"10.1016\/j.ajo.2020.11.019"},{"key":"74855","doi-asserted-by":"crossref","unstructured":"Han IC, Tadarati M, Pacheco KD, Scott AW. Evaluation of macular vascular abnormalities identified by optical coherence tomography angiography in sickle cell disease. Am J Ophthalmol. 2017; 177:90-99.","DOI":"10.1016\/j.ajo.2017.02.007"},{"key":"74856","doi-asserted-by":"crossref","unstructured":"Armenis I, Kalotychou V, Tzanetea R. Prognostic value of T786C and G894T eNOS polymorphisms in sickle cell disease. Nitric Oxide. 2017; 62:17-23.","DOI":"10.1016\/j.niox.2016.11.002"},{"key":"74857","doi-asserted-by":"crossref","unstructured":"Vicari P, Adegoke SA, Mazzotti DR, Can\u00e7ado RD, Nogutti MA, Figueiredo MS. Interleukin-1\u03b2 and interleukin-6 gene polymorphisms are associated with manifestations of sickle cell anemia. Blood Cells Mol Dis. 2015; 54(3):244-249.","DOI":"10.1016\/j.bcmd.2014.12.004"},{"key":"74858","doi-asserted-by":"crossref","unstructured":"Powars DR, Hiti A, Ramicone E, Johnson C, Chan L. Outcome in hemoglobin SC disease: a four-decade observational study of clinical, hematologic, and genetic factors. Am J Hematol. 2002; 70(3):206-215.","DOI":"10.1002\/ajh.10140"},{"key":"74859","unstructured":"Boehm CD, Dowling CE, Antonarakis SE, Honig GR, Kazazian HH Jr. Evidence supporting a single origin of the beta(C)-globin gene in blacks. Am J Hum Genet. 1985; 37(4):771-777."},{"key":"74860","doi-asserted-by":"crossref","unstructured":"Vatansever E, Vatansever M, Din\u00e7 E, Temel G, \u00dcnal S. Evaluation of ocular complications by using optical coherence tomography in children with sickle cell disease eye findings in children with sickle cell disease. J Pediatr Hematol Oncol. 2020; 42(2):92-99.","DOI":"10.1097\/MPH.0000000000001678"},{"key":"74861","doi-asserted-by":"crossref","unstructured":"Dell\u2019Arti L, Barteselli G, Riva L. Sickle cell maculopathy: identification of systemic risk factors, and microstructural analysis of individual retinal layers of the macula. PLoS One. 2018; 13(3):e0193582.","DOI":"10.1371\/journal.pone.0193582"},{"key":"74862","doi-asserted-by":"crossref","unstructured":"Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore). 2005; 84(6):363-376.","DOI":"10.1097\/01.md.0000189089.45003.52"},{"key":"74863","doi-asserted-by":"crossref","unstructured":"Serjeant BE, Mason KP, Acheson RW, Maude GH, Stuart J, Serjeant GR. Blood rheology and proliferative retinopathy in homozygous sickle cell disease. Br J Ophthalmol. 1986; 70(7):522-525.","DOI":"10.1136\/bjo.70.7.522"},{"key":"74864","doi-asserted-by":"crossref","unstructured":"Hayes RJ, Condon PI, Serjeant GR. Haematological factors associated with proliferative retinopathy in homozygous sickle cell disease. Br J Ophthalmol. 1981; 65(1):29-35.","DOI":"10.1136\/bjo.65.1.29"},{"key":"74865","doi-asserted-by":"crossref","unstructured":"al-Hazzaa S, Bird AC, Kulozik A. Ocular findings in Saudi Arabian patients with sickle cell disease. Br J Ophthalmol. 1995; 79(5):457-461.","DOI":"10.1136\/bjo.79.5.457"},{"key":"74866","doi-asserted-by":"crossref","unstructured":"Serjeant BE, Mason KP, Condon PI. Blood rheology and proliferative retinopathy in sickle cell-haemoglobin C disease. Br J Ophthalmol. 1984; 68(5):325-328.","DOI":"10.1136\/bjo.68.5.325"},{"key":"74867","doi-asserted-by":"crossref","unstructured":"Estepp JH, Smeltzer MP, Wang WC, Hoehn ME, Hankins JS, Aygun B. Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children. Br J Haematol. 2013; 161(3):402-405.","DOI":"10.1111\/bjh.12238"},{"key":"74868","doi-asserted-by":"crossref","unstructured":"Saadouli D, Yahyaoui S, Ben Issa S. Sickle cell retinopathy in children: report of 42 cases. J Fr Ophtalmol. 2020; 43(4):319-323.","DOI":"10.1016\/j.jfo.2019.09.005"},{"key":"74869","doi-asserted-by":"crossref","unstructured":"Samant S, Dhar SK, Sahu MC. Ophthalmic manifestation of sickle cell patients in Eastern India. J Clin Diagn Res. 2018; 12(7):13-15.","DOI":"10.7860\/JCDR\/2018\/36868.11810"},{"key":"74870","doi-asserted-by":"crossref","unstructured":"Lemaire C, Lamarre Y, Lemonne N. Severe proliferative retinopathy is associated with blood hyperviscosity in sickle cell hemoglobin-C disease but not in sickle cell anemia. Clin Hemorheol Microcirc. 2013; 55(2):205-212.","DOI":"10.3233\/CH-2012-1622"},{"key":"74871","doi-asserted-by":"crossref","unstructured":"Cruz PR, Lira RP, Pereira Filho SA. Increased circulating PEDF and low sICAM-1 are associated with sickle cell retinopathy. Blood Cells Mol Dis. 2015; 54(1):33-37.","DOI":"10.1016\/j.bcmd.2014.08.003"},{"key":"74872","doi-asserted-by":"crossref","unstructured":"Agouti I, Masson E, Loundou A. Plasma levels of E-selectin are associated with retinopathy in sickle cell disease. Eur J Haematol. 2023; 110(3):271-279.","DOI":"10.1111\/ejh.13902"},{"key":"74873","doi-asserted-by":"crossref","unstructured":"Mohan JS, Lip PL, Blann AD, Bareford D, Lip GY. The angiopoietin\/Tie-2 system in proliferative sickle retinopathy: relation to vascular endothelial growth factor, its soluble receptor Flt-1 and von Willebrand factor, and to the effects of laser treatment. Br J Ophthalmol. 2005; 89(7):815-819.","DOI":"10.1136\/bjo.2004.058164"},{"key":"74874","doi-asserted-by":"crossref","unstructured":"Elhawary EE, Khedr SF, Nagy HM, El-Bradey MH, Elshanshory MR. Correlation of asymmetric dimethyl arginine level to sickle retinopathy in children with sickle cell disease. J Pediatr Hematol Oncol. 2023; 45(1):e48-e51.","DOI":"10.1097\/MPH.0000000000002435"},{"key":"74875","unstructured":"Goldberg MF. Retinal vaso-occlusion in sickling hemoglobinopathies. Birth Defects Orig Artic Ser. 1976; 12(3):475-515."},{"key":"74876","doi-asserted-by":"crossref","unstructured":"Akinsheye I, Alsultan A, Solovieff N. Fetal hemoglobin in sickle cell anemia. Blood. 2011; 118(1):19-27.","DOI":"10.1182\/blood-2011-03-325258"},{"key":"74877","doi-asserted-by":"crossref","unstructured":"da Guarda CC, Yahou\u00e9d\u00e9hou S, Santiago RP. Sickle cell disease: a distinction of two most frequent genotypes (HbSS and HbSC). PLoS One. 2020; 15(1):e0228399.","DOI":"10.1371\/journal.pone.0228399"},{"key":"74878","doi-asserted-by":"crossref","unstructured":"Scott AW. Ophthalmic manifestations of sickle cell disease. South Med J. 2016; 109(9):542-548.","DOI":"10.14423\/SMJ.0000000000000525"},{"key":"74879","doi-asserted-by":"crossref","unstructured":"Myint KT, Sahoo S, Thein AW, Moe S, Ni H. Laser therapy for retinopathy in sickle cell disease. Cochrane Database Syst Rev. 2022; 12(12)","DOI":"10.1002\/14651858.CD010790.pub3"},{"key":"74880","doi-asserted-by":"crossref","unstructured":"Shaikh S. Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy. Indian J Ophthalmol. 2008; 56(3):259.","DOI":"10.4103\/0301-4738.40380"},{"key":"74881","doi-asserted-by":"crossref","unstructured":"Siqueira RC, Costa RA, Scott IU, Cintra LP, Jorge R. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. Acta Ophthalmol Scand. 2006; 84(6):834-835.","DOI":"10.1111\/j.1600-0420.2006.00779.x"},{"key":"74882","doi-asserted-by":"crossref","unstructured":"Padaro E, Kueviakoe IMD, Agb\u00e9tiafa K. Therapeutic phlebotomy during major sickle cell disease in Togo. Med Sante Trop. 2019; 29(1):106-107.","DOI":"10.1155\/2019\/4539675"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11879\/77921","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11879\/78323","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11879\/77921","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:52Z","timestamp":1794046072000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":85,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286420","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,19]]}}}